Stevie Vega
Adult Health · Montgomery, ALNPI 1073117248
Payments from drug & device makers
Across 103 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$349
- Novartis$258
- AbbVie$231
- Pfizer$184
- Axsome Therapeutics, Inc.$146
- Amgen$125
- plus $828 from 17 others
What the payments were for
- Food & beverage$2,121100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 17 | $349 |
| Novartis | 12 | $258 |
| AbbVie | 11 | $231 |
| Pfizer | 9 | $184 |
| Axsome Therapeutics, Inc. | 7 | $146 |
| Amgen | 6 | $125 |
| Acadia Pharmaceuticals Inc | 6 | $121 |
| Argenx US, Inc. | 5 | $103 |
| UCB, Inc. | 5 | $101 |
| Jazz Pharmaceuticals Inc. | 3 | $81 |
| Johnson & Johnson | 3 | $61 |
| Lilly USA, LLC | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Tanabe Pharma America, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $34 |
| Boston Scientific | 2 | $29 |
| EMD Serono, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Heron Therapeutics, Inc. | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Arteriocyte Medical Systems, Inc. | 1 | $16 |
How this compares
$2,121 in reported general payments places this provider in the 75th percentile of 308 adult health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sumatriptan Succinate | 14 | $275 |
Paid to pharmacies, not to this prescriber.
Other adult health in Montgomery
- Holly CluckMontgomery$12K
- Sonya TatumMontgomery$9K
- Jessica RollinsMontgomery$7K
- Holly VezertzisMontgomery$5K
- Wendy CantrellMountain Brk$276K
- Lanier OhareBirmingham$42K
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Olivia ViseHoover$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.